Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner

Treatment of pancreatic ductal adenocarcinoma (PDAC), a dismal disease with poor survival rates, is hampered by the high prevalence of chemotherapy resistance. Resistance is accompanied by macrophage infiltration into the tumor microenvironment, and infiltrated macrophages are key players in chemoth...

Descripción completa

Detalles Bibliográficos
Autores principales: Spek, C. Arnold, Aberson, Hella L., Duitman, JanWillem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869168/
https://www.ncbi.nlm.nih.gov/pubmed/35203429
http://dx.doi.org/10.3390/biomedicines10020219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8869168/
https://www.ncbi.nlm.nih.gov/pubmed/35203429
http://dx.doi.org/10.3390/biomedicines10020219

Ejemplares similares